Forum Expands Team
This article was originally published in Scrip
Forum Pharmaceuticals Inc., a company focused on treating brain diseases, has made a number of appointments to its team: George Parker chief human resources officer; Stephen Brannan vice president (VP) of clinical research and medical affairs; Diana Hughes VP of pharmacovigilance and medical risk management; Robert Pintar VP of supply chair operations and A.J. Sankoh VP of biostatics and statistical programming. Most recently Parker was VP of global human resources at Molecular Devices (a life sciences operating company of Danaher Corporation) and he previously was VP of human resources at Cyberbonics and PerkinElmer Instruments. Brannan brings 15 years' experience to Forum and previously held roles at Takeda, most recently being VP of CNS clinical science/PDD global therapeutics area head. Before this he held various positions at Novartis, Cyberonics and Eli Lilly. Previously Hughes was VP of worldwide safety and regulatory at Pfizer, Inc. and prior to this she was VP of worldwide safety and regulatory primary care business unit lead. Pintar has more than 25 years' experience and recently served as VP of supply chain for Cubist Pharmaceuticals and he has also held various positions in supply chain and materials management at companies including Sandoz/Novartis, Baxter BioScience and Sanofi Pasteur. Sanokh most recently was VP of biostatistics and clinical informatics at Synageva Biopharma and previously he held roles at Vertex Pharmaceuticals, Sanofi-Aventis and Genetics Institute/Wyeth Pharmaceuticals.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.